Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.

Stopped The laboratory's partner on this study decides to terminate the contract with the CHRU Brest, because of the difficulty of the recruitment.

Conditions

• Cerebral Lymphoma B Cell Refractory

Interventions

• DRUG: infusion of MYOCET

Sponsor

University Hospital, Brest

Collaborators

• [object Object]